American Century Companies Inc. Increases Stake in ADMA Biologics

Biotechnology firm sees institutional investment rise amid positive analyst sentiment

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

American Century Companies Inc. increased its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 1.8% during the 3rd quarter, according to a recent SEC filing. The firm now owns 4,695,923 shares of the biotechnology company's stock, representing a 1.97% stake worth $68.8 million.

Why it matters

The increase in institutional investment from a major asset manager like American Century Companies suggests growing confidence in ADMA Biologics' prospects. As a biopharmaceutical company focused on specialty plasma-derived biologics, ADMA has seen its stock rise amid positive analyst sentiment and the company's efforts to address unmet needs in immune-compromised patient populations.

The details

According to the filing, American Century Companies bought an additional 84,934 shares of ADMA Biologics during the 3rd quarter. This builds on the firm's existing position and underscores the institutional investor's belief in the company's long-term potential. ADMA Biologics is currently rated as a 'Buy' by Wall Street analysts, who cite the company's marketed product portfolio and integrated business model spanning plasma collection, fractionation, and manufacturing.

  • The SEC filing covers the 3rd quarter of the fiscal year.

The players

American Century Companies Inc.

A major asset management firm that oversees over $200 billion in assets and has increased its stake in the biotechnology company ADMA Biologics.

ADMA Biologics Inc.

A biopharmaceutical company focused on the development, manufacturing, and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases.

Got photos? Submit your photos here. ›

The takeaway

The increased investment from a respected institutional investor like American Century Companies suggests growing confidence in ADMA Biologics' ability to capitalize on opportunities in the specialty plasma-derived biologics market and address unmet medical needs. This reflects the company's progress in building out its integrated business model and marketed product portfolio.